Entheon Biomedical Corp.

Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the 'untreatable case' and 'lost cause' from the norm to the exception. We are committed to the legal development of regulated, safe & effective, psychedelic therapies, and in demonstrating their efficacy when administered in a scientifically-validated manner.

Recent News

  • Entheon Biomedical Announces Non-Brokered Private Placement Financing

    Vancouver, British Columbia--(Newsfile Corp. - April 5, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announces that it is proceeding on a non-brokered private placement financing of up to 30,000,000 Units (the "Units") at a price of CDN$0.10 per Unit for gross proceeds of up to CDN$3,000,000 (the "Placement"). Each Unit...

    2022-04-05 8:30 AM EDT
  • Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical Research Platform

    Vancouver, British Columbia--(Newsfile Corp. - March 29, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to announce that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. ("HaluGen"), is now available for sale in Canada and the United States.HaluGen's Psychedelics Genetic Test Kit...

    2022-03-29 8:30 AM EDT
  • Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT

    Vancouver, British Columbia--(Newsfile Corp. - March 15, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, today announced that the first patient has been enrolled in the EBRX-101 study, a comprehensive phase I clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of N, N-dimethyltryptamine (DMT). The Company enrolled the first EBRX-101...

    2022-03-15 8:30 AM EDT
  • Entheon Biomedical Announces EBIQ-101 First-Patient Dose

    Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provide an update on its Observational Study, EBIQ-101.We are pleased to report that the first patient has been dosed in EBIQ-101, a study using electroencephalography (EEG) to observe variability in neurological activity in...

    2022-02-24 8:30 AM EST
  • Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study

    Vancouver, British Columbia--(Newsfile Corp. - February 16, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is launching the upcoming EBIQ-101 Observational Trial ("EBIQ-101" or the "Trial") in partnership with Wavepaths LLC ("Wavepaths"). The study is taking place at Heading Health LLC ("Heading Health") with Dr. Steve Levine, MD, as principal investigator. Recruitment...

    2022-02-16 8:30 AM EST
  • Entheon Biomedical Announces the Approval of DMT Clinical Trial

    Vancouver, British Columbia--(Newsfile Corp. - February 3, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announced today the approval by the local Dutch ethics committee of EBRX-101, a comprehensive phase I clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of N,N-dimethyltryptamine (DMT). The study will be conducted at the Centre...

    2022-02-03 8:30 AM EST
  • Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

    Vancouver, British Columbia--(Newsfile Corp. - January 18, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, has announced an agreement with Psychedelics Today, LLC ("Psychedelics Today'') to help drive brand awareness of the Company's Psychedelics Genetic Test Kit, developed and commercialized by its wholly-owned subsidiary HaluGen Life Sciences Inc. ("HaluGen").The agreement with...

    2022-01-18 8:30 AM EST
  • Entheon Biomedical Corp. Files Preliminary Shelf Prospectus

    Vancouver, British Columbia--(Newsfile Corp. - January 18, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") announced that it has filed a preliminary short form base shelf prospectus dated January 14, 2022 (the "Preliminary Prospectus") with the securities commissions in each of the provinces and territories of Canada.The Preliminary Prospectus has not yet become final for the purpose of the sale of securities. Once the receipts for the final short form base shelf prospectus...

    2022-01-18 8:00 AM EST